GlassScriptPhysician profile
Richard E Landau
NPI 1235166901
$3,963.15
in general payments reported to CMS, 2019-2025
31 companies · $875 in 2025
The $875 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $162 · 2021: $260 · 2022: $316 · 2023: $599 · 2024: $812 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,187 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.77 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $785.11 | 2019-2025 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $462.98 | 2019-2025 | Erleada |
| Teleflex LLC | $422.51 | 2021-2025 | Urolift |
| Sumitomo Pharma America, INC. | $368.09 | 2023-2025 | Gemtesa, Orgovyx |
| Dentsply Ih Ab | $302.05 | 2024-2025 | Lofric |
| Neotract INC. | $221.52 | 2019-2020 | |
| Pfizer INC. | $203.01 | 2019-2025 | |
| Abbvie INC. | $154.91 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.90 | 2019-2023 | |
| Comsort, INC | $100.00 | 2019 | |
| Dentsply Ih INC. | $81.65 | 2022 | |
| 180 Medical, INC. | $81.07 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $68.49 | 2019-2025 | Adstiladrin |
| Boston Scientific Corporation | $66.82 | 2022-2025 | Rezum Generator, Solyx Sis System |
| Blue Earth Diagnostics | $61.53 | 2022-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $54.07 | 2023 | |
| Axonics, INC. | $53.74 | 2023-2024 | Axonics |
| Progenics Pharmaceuticals, INC. | $43.26 | 2023 | Pylarify |
| Rochester Medical Corporation | $38.34 | 2019-2021 | |
| Amgen INC. | $37.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.73 | 2024-2025 | |
| Myovant Sciences INC. | $36.18 | 2021 | |
| Telix Pharmaceuticals | $23.87 | 2023 | Illuccix |
| Urogen Pharma, INC. | $22.03 | 2025 | |
| Merck Sharp & Dohme LLC | $19.95 | 2023 | Lynparza, Keytruda |
| Cook Medical LLC | $18.53 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.16 | 2023 | Oxlumo |
| Immunitybio, INC. | $17.00 | 2024 | |
| Avadel Specialty Pharmaceuticals, LLC | $15.87 | 2019 | |
| Endo Pharmaceuticals INC. | $13.77 | 2020 | |
| Coloplast Corp | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Landau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.